Alpha-1 antitrypsin deficiency (AATD) is caused by mutations in a single gene called SERPINA1 and follows an autosomal codominant inheritance pattern, meaning both copies of the gene you inherit actively contribute to how much functional protein your body produces. The condition is far more common than most people realize: worldwide estimates put the number of carriers at roughly 116 million, with about 3.4 million people carrying two deficiency alleles.1Chest. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys What makes AATD genetics particularly interesting is that the inheritance pattern does not behave like a simple dominant-or-recessive trait, and the specific combination of alleles you carry shapes not just whether you get sick but which organs are at risk.
The SERPINA1 Gene and What It Makes
The protein at the center of this condition, alpha-1 antitrypsin (AAT), is produced mainly by liver cells and released into the bloodstream. Its primary job is to protect the lungs by neutralizing enzymes released by immune cells called neutrophils. When neutrophils respond to infection or irritation, they release powerful proteases that can chew through lung tissue. AAT acts as a molecular trap: it lures the protease into cutting a specific loop in the AAT molecule, then snaps shut around it, permanently disabling the enzyme and allowing the complex to be cleared from the body.2PubMed Central. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application Beyond this protease-blocking role, AAT also tamps down inflammation by interacting with a broad array of immune signals and cell surfaces.3PubMed Central. The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
The SERPINA1 gene sits on chromosome 14 within a cluster of related genes that likely arose through ancient gene duplication.4PubMed Central. Novel SERPINA1 Alleles Identified through a Large Alpha-1 Antitrypsin Deficiency Screening Program and Review of Known Variants Every person carries two copies, one from each parent. The alleles are named using the “Pi” (protease inhibitor) system, and there are well over a hundred known variants. The normal allele is called Pi*M. Most people carry two copies of it (PiMM) and produce normal levels of AAT. The trouble begins with the deficiency alleles.
The Major Deficiency Alleles
Two mutations account for the vast majority of clinically significant AATD. The Pi*Z allele results from a single amino acid swap, where a glutamic acid at position 342 is replaced by a lysine.5PubMed Central. Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response The Pi*S allele involves a different substitution at position 264. Both are common enough to appear in routine genetic testing, but they cause problems through somewhat different mechanisms and to different degrees.6Journal of Chronic Obstructive Pulmonary Disease (JCOPDF). Intraindividual Variability in Serum Alpha-1 Antitrypsin Levels
The Z mutation is the more severe of the two. It causes the AAT protein to misfold in liver cells. Instead of being secreted normally into the bloodstream, the misfolded Z protein gets stuck in the endoplasmic reticulum, the cell’s protein-packaging compartment. More than 85% of the Z variant protein is retained inside the cell rather than released.7Journal of Biological Chemistry. Accumulation of the insoluble PiZ variant of human alpha 1-antitrypsin within the hepatic endoplasmic reticulum does not elevate the steady-state level of grp78/BiP Most of that retained protein gets degraded, but a small fraction resists breakdown and gradually builds up as insoluble clumps inside liver cells. This accumulation is visible under a microscope as characteristic inclusions and is directly linked to liver damage in both animal models and humans.8PubMed. Alpha-1-antitrypsin deficiency: accumulation or degradation of mutant variants within the hepatic endoplasmic reticulum
The S mutation reduces AAT levels to a milder degree and does not cause the same kind of protein buildup in liver cells. People who are homozygous for S (PiSS) tend to have about 60% of normal AAT levels, which is usually enough to avoid significant lung or liver disease on its own. The S allele becomes more clinically relevant when combined with Z.
Then there are the Null alleles, sometimes written as Pi*Q0, which are far rarer and far more consequential for the lungs. Null mutations lead to a complete absence of AAT protein, either because the gene produces a truncated, nonfunctional protein or because it produces nothing at all. People homozygous for Null alleles have undetectable AAT levels and tend to develop severe emphysema earlier in life than even ZZ individuals.9PubMed. Alpha-1 antitrypsin Null mutations and severity of emphysema A recently reported case involved a 35-year-old woman who had never smoked but developed end-stage lung disease requiring a transplant, caused by a novel homozygous Null mutation.10PubMed Central. Alpha-1 Antitrypsin Deficiency in a Young Never Smoker With Novel Pi*Null Homozygous Mutation: a Case Report Paradoxically, Null alleles cause less liver disease than Z alleles because there is no misfolded protein accumulating in hepatocytes; the damage to the lungs comes purely from having no circulating protease protection.
What Codominant Inheritance Means in Practice
In a simple recessive condition, carriers with one defective copy and one normal copy show no effects. AATD does not work that way. Because inheritance is codominant, each allele independently contributes its share of protein to the bloodstream. If you carry one M allele and one Z allele (PiMZ), you produce a normal amount from your M gene and a reduced amount from your Z gene. Your total AAT level ends up at roughly 50–65% of normal. That is usually enough to protect the lungs over a lifetime, but it is not nothing.
For a long time, MZ carriers were considered clinically unaffected. More recent evidence complicates that picture. A study of people with metabolic liver disease found that carrying even a single Z allele roughly doubled the risk of progressing to advanced liver disease, including cirrhosis and liver-related death.11Annals of Hepatology. Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH Liver fibrosis measurements in MZ carriers were slightly but measurably elevated compared to the general population.12PubMed Central. Alpha-1 antitrypsin deficiency and Pi*Z allele as important co-factors in the development of liver fibrosis This does not mean every MZ carrier will develop liver problems, but it does mean that MZ status can matter when other risk factors are present, such as obesity, alcohol use, or underlying metabolic disease.
The SZ combination presents an intermediate risk. People with PiSZ produce reduced AAT from both alleles, typically ending up with about 35–40% of normal levels. They can develop progressive liver disease similar to that seen in ZZ individuals and need monitoring.13PubMed Central. Alpha-1 antitrypsin deficiency liver disease For lung disease, the risk for SZ individuals sits between that of MZ carriers and ZZ homozygotes, particularly if they smoke.
Two Diseases from One Gene
AATD is unusual in that the same genetic defect causes disease through two completely different pathways depending on which organ you are looking at. In the lungs, the problem is straightforward deficiency: too little AAT circulating in the blood means neutrophil proteases go unchecked, gradually destroying the delicate walls of the air sacs. This leads to emphysema, typically starting in the lower lobes and presenting earlier than smoking-related emphysema. The process involves a chain of reinforcing damage: protease activity, oxidative stress, and cell death amplify each other.14PubMed Central. Lung disease associated with alpha1-antitrypsin deficiency
In the liver, the problem is not deficiency but accumulation. The misfolded Z protein piles up inside hepatocytes, triggering inflammation that can progress to fibrosis, cirrhosis, and even liver cancer.15PubMed Central. Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Approaches and Future Directions This is why AATD is the most common genetic cause of liver disease in children and the leading inherited reason for pediatric liver transplantation. Roughly 4 to 10 percent of affected children develop clinically significant liver disease in their first two decades.16PubMed Central. Alpha-1-Antitrypsin Deficiency: An Important Cause of Pediatric Liver Disease Yet most ZZ children never come to medical attention at all for liver disease.13PubMed Central. Alpha-1 antitrypsin deficiency liver disease
This organ-specific split has a practical consequence: Null allele carriers, who make no protein at all, face severe lung risk but relatively little liver risk because there is no protein to accumulate. ZZ individuals, by contrast, have both a lung deficiency problem and a liver accumulation problem simultaneously.
Why People with the Same Genotype Get Different Outcomes
One of the most striking features of AATD is how variable the disease is, even among people with identical genotypes. Two siblings who are both PiZZ can follow dramatically different trajectories: one develops severe emphysema by age 40 while the other remains relatively healthy into their 60s. Researchers have identified two broad categories of explanation: environmental exposures and modifier genes elsewhere in the genome.
Cigarette smoking is the single most important environmental accelerant. The connection is almost poetically precise. AAT’s active site contains a methionine residue that is essential for its ability to trap proteases. Oxidants in cigarette smoke chemically modify that methionine, converting it to methionine sulfoxide and disabling AAT’s protective function.17PubMed Central. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity Even in people with normal AAT levels, smoking reduces the functional activity of whatever AAT reaches the lungs.18PubMed. Cigarette smoke inhalation decreases alpha 1-antitrypsin activity in rat lung Alveolar immune cells from smokers’ lungs release enough oxidants to inactivate AAT directly, creating a local zone of protease vulnerability.19PubMed Central. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase For someone who is already severely deficient in AAT, this oxidative hit on top of low protein levels can be catastrophic.
Beyond smoking, modifier genes are suspected to play a large role but have been hard to pin down. Genome-wide studies suggest that variants outside of SERPINA1, including genes involved in general lung function in the broader population, likely influence how quickly or severely lung disease develops in AATD.20PubMed Central. Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency-associated associated lung disease: a look at future precision medicine approaches The honest state of this research is that individual modifier genes have been proposed but most have not been reliably replicated across different study populations.21PubMed Central. Why is Disease Penetration So Variable? Role of Genetic Modifiers of Lung Function in Alpha-1 Antitrypsin Deficiency The idea that a “polygenic risk score” for lung function might eventually help predict which AATD patients will develop severe disease is being explored, but it remains early-stage work.
Vasculitis and Other Complications Beyond the Lungs and Liver
While emphysema and liver disease get the most attention, AATD has been linked to conditions that at first glance seem unrelated. One of the better-documented associations is with systemic vasculitis, an inflammatory condition affecting blood vessels throughout the body. Studies have found that the PiZ allele appears in patients with ANCA-positive systemic vasculitis at rates well above what would be expected from the general population.22PubMed. alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications One series of patients with severe AATD and vasculitis documented involvement of a median of eight organs per patient, with skin, kidney, and joint damage being nearly universal, and the majority of patients also had emphysema or liver abnormalities.23QJM: An International Journal of Medicine. Systemic necrotizing vasculitides in severe alpha1-antitrypsin deficiency
The proposed explanation involves one of the key immune targets in vasculitis, a neutrophil protein called proteinase-3 (PR3). AAT normally helps keep PR3 activity in check. When AAT is deficient, unchecked PR3 on neutrophil surfaces may trigger autoimmune responses and antibody formation against it, fueling the vascular inflammation.24PubMed. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis The connection is uncommon enough that most people with AATD will never develop vasculitis, but it highlights that AAT’s protective role extends well beyond the lungs.
Testing and the Newborn Screening Debate
Diagnosing AATD generally involves measuring the AAT level in the blood and then determining which alleles a person carries through genotyping. When the genotype and the protein level do not match up as expected, a third method called phenotyping can help identify unusual or novel variants.25Clinical Chemistry. Diagnosis of α-1-Antitrypsin Deficiency: An Algorithm of Quantification, Genotyping, and Phenotyping This combination approach matters because there are dozens of rare alleles that standard genotyping panels might miss, including the growing list of Null variants and novel mutations found through large-scale screening programs.4PubMed Central. Novel SERPINA1 Alleles Identified through a Large Alpha-1 Antitrypsin Deficiency Screening Program and Review of Known Variants
Whether to screen newborns for AATD has been debated for decades. Sweden ran a large newborn screening program starting in the 1970s. The theoretical benefits are appealing: identifying affected children early could enable targeted anti-smoking counseling before adolescence, close monitoring for liver disease, and genetic counseling for families. But the objections have been real too. Most ZZ children will never develop symptomatic liver disease in childhood, so screening identifies many families who will spend years worrying about a risk that may never materialize. Early screening programs also raised concerns about discrimination by insurers and employers, and about the psychological burden placed on parents during a vulnerable period.26Acta Paediatrica. A future for neonatal α1‐antitrypsin screening?
The landscape has shifted since those early debates. Legal protections against genetic discrimination have expanded in many countries, genetic counseling has become more sophisticated, and treatment options have grown from basic supportive care to augmentation therapy and, soon, gene-based approaches. A systematic review of the newborn screening literature noted that the arguments against screening were largely formulated in the 1970s and 1980s, and the intervening decades have reshaped the risk-benefit calculus considerably.27American Journal of Respiratory and Critical Care Medicine. Newborn Screening in Alpha-1 Antitrypsin Deficiency: A Systematic Review Even so, the debate remains active, particularly around the question of whether identifying an asymptomatic newborn as ZZ truly changes outcomes enough to justify the anxiety and cost.28PubMed Central. Appropriateness of newborn screening for α1-antitrypsin deficiency
Gene Therapy and Next-Generation Treatments
Current treatment for AATD lung disease centers on augmentation therapy, which involves regular intravenous infusions of purified AAT protein from donor plasma. It works, but it is expensive, requires lifelong infusions, and addresses only the lung deficiency side of the equation. It does nothing to stop the accumulation of misfolded protein in the liver.29PubMed Central. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease
Gene therapy aims to change that calculus fundamentally. Early approaches used viral vectors to deliver a working copy of the SERPINA1 gene into muscle or liver cells, hoping the body would then produce its own normal AAT. More recent work has moved toward gene editing, where the goal is not to add a new gene but to correct the existing mutation directly. One approach targets the Z mutation’s RNA, recruiting the body’s own editing enzymes to convert the mutant sequence back to the normal version at the RNA level, so the cell produces functional AAT without any permanent change to the DNA.30PubMed. Editing Approaches to Treat Alpha-1 Antitrypsin Deficiency
Another strategy uses base editors delivered by specially engineered lipid nanoparticles that can reach both the liver and the lungs simultaneously. In preclinical work, these nanoparticles corrected the disease-causing mutations in both organs, which is significant because most delivery systems can target one or the other but not both.31PubMed Central. Delivering base editors to the liver and lungs in alpha-1 antitrypsin deficiency If this dual-organ approach works in humans, it would be the first treatment capable of addressing both the lung deficiency and the liver accumulation at once.
On the small-molecule front, researchers have identified compounds that bind to the misfolded Z protein and physically prevent it from clumping together. One lead compound increased secretion of Z AAT threefold in human cell models and sevenfold in the plasma of transgenic mice after oral dosing.32PubMed Central. Development of a small molecule that corrects misfolding and increases secretion of Z α(1) -antitrypsin The idea is elegant: rather than replacing the gene or editing the mutation, you take the protein the body is already making and help it fold correctly enough to leave the cell. This would simultaneously raise blood AAT levels and reduce the toxic accumulation in the liver. Several compounds along these lines have entered or are approaching clinical trials.
How Widely the Gene Variants Are Distributed
AATD is sometimes described as a condition primarily affecting people of Northern European descent, and the Z allele is indeed most common in Scandinavian and Northwestern European populations. But large epidemiological surveys have found deficiency alleles across a surprisingly wide range of ethnic groups, including populations across the Middle East, Central and Southeast Asia, North Africa, and among African-descended populations in multiple countries.1Chest. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys The S allele has a particularly high frequency in the Iberian Peninsula and is common throughout Southern Europe and parts of North Africa.
This global distribution matters because physicians in many regions do not think to test for AATD, assuming it is a “Northern European disease.” The result is widespread underdiagnosis. Studies consistently find that the average AATD patient waits years between first symptoms and correct diagnosis, partly because the condition mimics common forms of COPD and asthma that are chalked up to smoking or environment. If you have unexplained emphysema, especially at a younger age or with lower-lobe predominance, testing for AATD is worth pursuing regardless of your ethnic background. The same applies if you have unexplained liver disease, particularly in childhood, or if multiple family members have had lung or liver problems without clear environmental explanations.